Does Dr. ABUBAKAR ABDUL-RAHMAN have financial conflicts of interest?

Dr. ABUBAKAR ABDUL-RAHMAN (NP) has received a total of $26,973 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $26,973 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ABUBAKAR ABDUL-RAHMAN?

According to CMS Open Payments data, Dr. ABUBAKAR ABDUL-RAHMAN received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($24,018), OTSUKA AMERICA PHARMACEUTICAL ($641), and AXSOME THERAPEUTICS ($320).

Does Dr. ABUBAKAR ABDUL-RAHMAN receive research grants or speaking fees?

Dr. ABUBAKAR ABDUL-RAHMAN has received $26,973 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. ABUBAKAR ABDUL-RAHMAN

NPReal-Time Hydrated

Specialty: Nurse Practitioner, Primary Care

Practice Location: SEATTLE, WA 98108

NPI Number: 1689939001

LIFETIME INDUSTRY VALUE

$26,973

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ABDUL-RAHMAN is a verified Nurse Practitioner, Primary Care practitioner based in SEATTLE, WA.

Between 2021 and 2025, Dr. ABDUL-RAHMAN had an overall industry promotional and research financial footprint of $26,973 as recorded in the federal CMS Open Payments database.

$26,973 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDUL-RAHMAN's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $24,018 (representing 89% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$24,018

89%

OTSUKA AMERICA PHARMACEUTICAL

Rank 2

$641

2.4%

AXSOME THERAPEUTICS

Rank 3

$320

1.2%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.